RUNNING TITLE: Anti-invasive effect of SST in human tumoral cells
INTRODUCTION
Neuroblastoma is the most frequent extracranial solid tumour in children; metastatic disease is found in more than 50% of the patients at the time of diagnosis and is indicative of a poor prognosis. The most frequent metastatic sites are bone, bone marrow, liver and (more rarely) the central nervous system (1) .
Crucial events for the invasion and spread of tumoral cells are the ability to digest the extracellular matrix, migrate, cross blood vessel walls and reach the circulation.
It is well known that many growth factors can produce some of the characteristic features of invasive growth like proliferation, motility and increased survival. Among these, platelet-derived growth factor (PDGF) 1 , a mitogen mostly for cells of mesenchymal origin, was shown to induce chemotaxis and actin reorganization and prevent cells from dying by apoptosis (2) . As a variety of other neural crest-derived tumour cell lines, neuroblastoma cells express specific transcripts of PDGF genes and both α-and β-PDGF receptor genes (3, 4) . It is feasible that the simultaneous presence of PDGF and its receptor genes contributes to tumour cell growth and motility by means of an autocrine mechanism. Furthermore, a paracrine mechanism may also be active as the surrounding tissues or cells present in tumours, such as macrophages and endothelial cells, produce PDGF.
Somatostatin (SST) is a peptide that is widely distributed throughout the central nervous system and peripheral tissues. Somatostatin has multiple physiological functions, including neuromodulatory actions, inhibition of secretion of growth hormone, and of many other hormones produced by the hypothalamus, pituitary and gastrointestinal tract (5, 6) . Moreover, somatostatin has been shown also to possess an antiproliferative effect in some human cancers including breast cancer, pancreatic cancer, small cell lung carcinoma and neuroblastoma (7, 8) .
The effect of somatostatin are mediated by a family of five different G-protein coupled receptors, which are variably expressed in both normal tissues and tumours, with many cell lineages expressing two or more subtypes. It has been suggested that somatostatin receptor (SSTR) expression is a favourable prognostic factor in human neuroblastoma because high levels of SSTR type 2 positively relate to patient survival (9, 10) . In previous studies, we have shown that somatostatin inhibits proliferation, ERK 1/2 and Ras activity in SH-SY5Y cells (11, 12) , and that these cells express all five SSTR subtypes (13) . Moreover, it has also been reported that somatostatin can inhibit human endothelial-like EAhy926 cell invasion and monocyte migration (14) , and these effects have been related to its ability to impair the angiogenic process.
On the basis of the above results, we tested the effect of somatostatin on the motility and invasion of PDGF-stimulated SH-SY5Y cells, and found that it potently and efficiently inhibits migration and invasion via a mechanism that depends partly on ERK inhibition and partly on the small Gprotein Rac inhibition. We suggest that somatostatin may be useful for controlling invasive growth in neuroblastoma.
EXPERIMENTAL PROCEDURES
Reagents and antibodies -The platelet-derived growth factor-BB (PDGF-BB), pertussis toxin, somatostatin, PD98059 and wortmannin were from Sigma Chemicals (St. Louis, MO, USA).
Collagen type IV and Matrigel, a solubilized basement membrane preparation extracted from Cell culture -The human neuroblastoma cell line SH-SY5Y was routinely grown in RPMI medium (Sigma Chemicals, St. Louis, MO, USA), supplemented with 10% heat-inactivated fetal bovine serum (FBS), in a humified atmosphere of 5% CO 2 in air at 37°C. Before all the experiments, the cells were serum-deprived for 24 hours.
Cell migration and invasion assays -SH-SY5Y cell migration and invasion were evaluated by means of chemotaxis and chemoinvasion experiments respectively, in a 48-well modified Boyden chamber. With the migration assay, we assessed the ability of the cells to migrate toward a chemoattractant on a two-dimensional substrate (in our case, collagen type IV). The invasion assay, introducing the use of Matrigel as a three-dimensional matrix, gives information not only about growth factor-induced cell motility, but also about the ability of the cells to cross tissue barriers (for a review, see 15) . This latter in vitro test allows the rapid and quantitative assessment of invasiveness and a mean to screen for drugs which alter the invasive phenotype of tumour cells (16) . Briefly, the chemotaxis experiments were performed using 8 µm Nuclepore polyvinylpyrrolidine(PVP)-free polycarbonate filters coated with 10 µg/ml of type IV collagen and placed over a bottom chamber containing 20 ng/ml PDGF as the chemo-attractant factor. Serumfree medium was used as a negative control. Suspended in RPMI medium containing 0.1% fatty acid-free bovine serum albumin (BSA), the SH-SY5Y cells were pretreated for 30 minutes with somatostatin or its analogues, and then added to the upper chamber at a density of 3 x 10 4 cells/well in the presence of the drugs. After six hours' incubation at 37°C, the non-migrated cells on the upper surface of the filter were removed by scraping; the cells that had migrated to the lower side of the filter were stained with Diff-quick stain (VWR Scientific Products, Bridgeport, NJ, USA), and 5-8 unit fields per filter were counted at 160X magnification using a Zeiss microscope. The assays were run in triplicate. For the chemoinvasion assays, the filters were coated with a layer of Matrigel (100 µg/filter), and the Boyden chamber was assembled with the coated side of the filter facing the cells in the upper compartment. The assays were then performed as described for chemotaxis.
Western blot analysis -Quiescent SH-SY5Y cells, treated as indicated, were washed with phosphate-buffered saline, and directly lysed in SDS-PAGE sample buffer (62 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (SDS), 10% glycerol, 5% 2-mercaptoethanol, and 0.04% bromophenol blue). After SDS-PAGE electrophoresis, proteins were transferred onto nitrocellulose membranes that were blocked with 5% (w/v) non fat dried milk in Tris-buffered saline containing 0.05% Tween 20, and incubated with the indicated primary antibodies. After incubation with the appropriate secondary antibody conjugated to peroxidase (DAKO, Denmark), the immunoreactive bands were visualized with chemioluminescence (ECL, Amersham, UK).
Rac activity assay -The levels of Rac-GTP were measured by affinity precipitation using GST-CRIB (Cdc42 and Rac interactive region) of PAK65 (17), as described previously (18) . Briefly, activated Rac-GTP was precipitated from whole cell lysates, prepared in lysis buffer containing 50 mM Tris-HCl pH 7.2; 500 mM NaCl; 1% Triton X-100; 0.5% sodium deoxycholate; 0.1% SDS; 1 mM sodium orthovanadate; 0.5 mM phenylmethylsulfonyl fluoride (PMSF); 10 µg/ml leupeptin and 10 µg/ml aprotinin, with 20 µl glutation agarose beads coupled with GST-CRIB. After 12.5%
SDS-PAGE, active Rac protein was detected by Western blotting using a monoclonal anti-Rac antibody. The densitometric analysis of the immunoblots was performed using the National Institute of Health (NIH) Image program.
Immunofluorescence -Quiescent SH-SY5Y cells, plated on glass coverslips coated with 10 µg/ml collagen IV and treated as indicated, were fixed in 4% paraformaldehyde and permeabilised with 0.3% Triton X-100. Fluorescein isothiocyanate (FITC)-labelled phalloidin (Sigma) was used to detect filamentous actin. The confocal images were obtained using a Bio-Rad MRC-1024 confocal microscope.
RESULTS

PDGF-stimulated motility and invasiveness in SH-SY5Y cells
We have previously reported the proliferative effect of PDGF on the SH-SY5Y human neuroblastoma cell line (13) . In this study, we investigated its ability to stimulate motility and invasion in SH-SY5Y cells by using chemotaxis and chemoinvasion experiments. The chemotaxis assays show the ability of the cells to migrate toward a chemoattractant (PDGF) on a twodimensional substrate. The chemoinvasion assays show the additional ability to cross a tissue barrier represented by the Matrigel (for more details, see Experimental Procedures). As shown in Figure 1 , PDGF stimulated migration and invasion in a concentration-dependent manner, with an EC 50 of about 5 ng/ml for both phenomena. The peak stimulatory effect was reached at a concentration of 20 ng/ml, corresponding to an increase from baseline of 9.27 ± 1.09 times in chemotaxis (16.4 ± 0.6 cells/field) and 9.57 ± 0.35 times in chemoinvasion (10.9 ± 2.6 cells/field).
Depending on the cell type, various signalling pathways have been shown to be involved in PDGFinduced cell motility (19) . The phosphatidylinositol 3-kinases (PI3-K) are a family of lipid kinases that phosphorylate the 3'-OH group of the inositol ring of membrane-bound phosphoinositides. The main phospholipid formed (phosphatidylinositol-3,4,5-trisphosphate, PIP 3 ) and the protein kinase that is activated by it -AKT -trigger a cascade of responses from cell growth and proliferation to survival and motility (20) . On the other hand, also the mitogen-activated protein kinase (MAPK) pathways are crucial signal transducing systems which are involved in the regulation of important cellular processes like cell proliferation, cell survival and also, in some cases, cell motility (21).
These physiological events are mainly regulated by the extracellular signal-regulated kinases 1 and 2 (ERK 1/2), which are the most widely expressed enzymes belonging to the MAPK family.
To elucidate the pathways responsible for the pro-migratory effect of PDGF on SH-SY5Y cells, the cells were pretreated for 30 min with 100 nM wortmannin to block the PI3-K pathway or 10 µM PD98059 to block the ERK 1/2 pathway. The results shown in Figure 2 demonstrate that both drugs reduced PDGF-stimulated migration, with an inhibition of respectively 63 ± 8.8% and 57 ± 11% (n=6). A similar inhibitory effect of PD98059 and wortmannin on PDGF-induced invasion was also observed (Figure 2 ), thus suggesting that both pathways are required for the PDGF stimulation of migration and invasion in SH-SY5Y cells.
Somatostatin inhibits PDGF-induced migration and invasion in SH-SY5Y cells
SSTRs are widely expressed in tumours (22) , and their activation is responsible for the peptide's direct antiproliferative effect (8) . In order to verify whether somatostatin possesses anti-migratory and anti-invasive properties, we studied its effects on PDGF-induced motility and invasion in SH-SY5Y cells, previously characterised in our laboratory for the expression of multiple SSTR subtypes (13) . Pretreatment of the cells with somatostatin inhibited the migration and invasion induced by PDGF 20 ng/ml in a concentration-dependent manner ( Figure 3 ). Peak inhibition of both phenomena (about 50%) was reached at a somatostatin concentration of 1 µM. The estimated IC 50 s for migration and invasion were respectively approximately 10 nM and 1 nM. Somatostatin did not inhibit cell motility and invasiveness in the absence of motogenic stimuli: i.e. in the absence of PDGF (data not shown).
Effect of Somatostatin analogues on PDGF-induced migration and invasion
SH-SY5Y cells express all five SSTR subtypes (13) . In an attempt to define the receptor subtype(s) responsible for the anti-migratory and anti-invasive effects of somatostatin in SH-SY5Y cells, we the compounds used in our experiments were described in a previous report (13) , where it is shown that each analogue binds to the specific receptor subtype with an affinity 50-100 times higher than to the other ones. As shown in Figure 4A .67 nM respectively, and >200 nM for the other receptor subtypes). The inhibitory effect ranged from 25 ± 6% (n=4) for Bim 23120 to 44.5 ± 11.6% (n=4) for Bim 23244, but variance analysis failed to reveal statistically significant differences between the various treatments.
All of the above analogues also repressed the invasive process induced by PDGF ( Figure 4B ) with very similar percentages of inhibition (about 40%).
The inhibitory effect of Somatostatin on cell motility is reverted by Pertussis toxin treatment
It 
Effect of Somatostatin on PDGF-induced ERK and PI3-K activation in SH-SY5Y cells
As mentioned above, the activation of both ERK and PI3-K pathways is required for the migratory and invasive effects of PDGF on SH-SY5Y cells (Figure 2 ). We therefore evaluated the possibility that the inhibitory effect of somatostatin might be mediated by its ability to interfere with the PDGF-induced activation of these intracellular pathways. We have previously shown (11, 13) that somatostatin inhibits PDGF-induced ERK 1/2 activation in SH-SY5Y cells (also see Figure 6B , lane 5). Thus, this finding indicates that somatostatin acts on at least one of the mechanisms required for PDGF-induced motility and invasion. AKT is a protein kinase recruited to the membrane and activated by phosphorylation as a direct consequence of PI3-K activity (20) . In this study, we evaluated AKT phosphorylation levels to test whether somatostatin is also capable of inhibiting PDGF-induced PI3-K activation. As shown in Figure 6A , somatostatin 1 µM did not modify the 
Somatostatin inhibits PDGF-induced Rac activation in SH-SY5Y cells
The remodelling of the actin cytoskeleton in response to migratory stimuli implies the activation of the small Rac and Rho G-proteins (25), which we evaluated as possible targets for the anti- As in the case of migration and invasion, the somatostatin-induced inhibition of Rac was also reverted by Pertussis toxin treatment ( Figure 8A ). A densitometric analysis is shown in Figure 8B .
Somatostatin inhibits PDGF-induced membrane ruffle formation
The movement of cells in response to chemoattractants or growth factors is mediated by coordinated changes in the actin cytoskeleton that involve the remodelling of cortical actin filaments in lamellipodia or membrane ruffles (26) . Membrane ruffle formation depends on the small Rac G-protein (27) . Somatostatin inhibits PDGF-induced Rac activation in SH-SY5Y cells (Figure 7) , and so, in order to investigate the correlation of this with actin cytoskeleton remodelling, we performed immunofluorescence experiments using FITC-labelled phalloidin to detect actin filaments.
As shown in Figure 9 , serum-deprived SH-SY5Y cells contain cortical actin bands but lack membrane ruffles (panel 1). Stimulation with PDGF (20 ng/ml for 5 min) led to the rapid reorganisation of actin to form membrane ruffles ( Figure 9 , panel 2). Pretreatment with somatostatin 1 µM for 30 min reduced the formation of membrane ruffles induced by PDGF ( Figure   9 , panel 3), thus showing a morphological correspondence with the inhibition of Rac activity.
DISCUSSION
About 50% of the children with neuroblastoma show bone, bone marrow and liver metastases at the time the disease is diagnosed (1), which demonstrates the highly invasive behaviour of the tumour.
In this study, we found that PDGF, which acts as an autocrine and paracrine growth factor in neuroblastoma cells, is also a very potent promoter of the motility and invasion of SH-SY5Y cells.
However, our most interesting finding is that somatostatin potently inhibits the invasive effects of PDGF (IC 50 s in the low nanomolar range). It has previously been suggested that SSTRs (particularly subtype 2, the most widely expressed subtype together with SSTR1) might be a useful therapeutic target in neuroblastoma (9) because of the antiproliferative effect of somatostatin, which we have also found in previous studies (11, 13) . Furthermore, clinical trials have shown that high levels of SSTR2 expression positively correlate with patient survival (10) . Our data showing that somatostatin is also a potent antimigratory and anti-invasive agent for neuroblastoma indicate that it could be used to limit the spread of tumour cells: i.e. the metastatic process. Moreover, the antiinvasive effect of somatostatin was not restricted to neuroblastoma cells, but was observed also in other highly invasive tumoural cell lines derived from human glioblastoma 2 , suggesting that this effect might be a general property of somatostatin.
After having found this anti-invasive effect, which may be clinically relevant, we investigated the signalling mechanisms used by PDGF to promote the invasive behaviour, and the molecular target responsible for the inhibitory effect of somatostatin.
Cell movement is a complex process involving a number of steps, including the disruption of cellcell junctions, cytoskeletal rearrangements and the constant remodelling of adhesive contacts with the extracellular matrix. From a morphological point of view, the formation of membrane ruffles is the first event arising from the PDGF-mediated reorganisation of the actin cytoskeleton; we found that somatostatin is capable of inhibiting this formation.
In molecular terms, it is generally agreed that PI3-K plays a crucial role in the signalling that regulates cell movement induced by different growth factors including hepatocyte growth factor, nerve growth factor and insulin-like growth factor (19) . Wortmannin, the most widely used PI3-K pathway blocker, inhibits the PDGF-induced migration and invasion of SH-SY5Y cells. However, the ERK 1/2 pathway also quite potently interferes with the regulation of cell motility as PD98059
(a specific blocker of enzyme activation) had an inhibitory effect on PDGF-stimulated migratory behaviour. The role of ERK 1/2 in PDGF-induced motility is controversial and could depend on the cell type studied. The PDGF-induced chemotaxis of Rat1 fibroblasts was unaffected by PD98059 treatment (28) . In contrast, the chemotactic response to PDGF was dependent on ERK 1/2 in human mesangial cells (29) and retinal pigment epithelial cells (30) . Our data support the idea that the PI3-K and ERK pathways both mediate PDGF-stimulated motility responses in neuroblastoma cells. We have previously shown that somatostatin inhibits MAPK activity in neuroblastoma cells (11, 13) , and so it is likely that one of the mechanisms responsible for its antimigratory and anti-invasive effects resides in the inhibition of this enzyme. In SH-SY5Y cells, somatostatin also inhibits PDGFstimulated Ras activation (12, 13) ; however, unlike the somatostatin-induced inhibition of migration, Ras inhibition is not Pertussis toxin-sensitive and requires the simultaneous activation of receptor subtypes 2 and 5 (13) . On the basis of these data, it can be concluded that Ras inhibition is not involved in the antimigratory action of somatostatin.
With reference to the PI3-K signalling route, one of the main downstream targets of enzyme activity is Rac, a member of the Rho family of small GTP-binding proteins involved in various types of actin rearrangements that are important for cell motility (25) . The crucial role of Rac in PDGFinduced cell motility has been clearly demonstrated using the overexpression of wild type Rac (28) and, on the other hand, a dominant negative Asn 17 Rac (31). We found that somatostatin does not directly affect PI3-K activity, but potently interferes with the Rac activation induced by PDGF, thus suggesting that it acts on the pathway between PI3-K and Rac. This pathway has been recently investigated (but not totally clarified), and implies the involvement of Rac-specific guanine nucleotide exchange factors (GEFs) such as Vav, Tiam-1 and Sos-1, which generally form multimolecular complexes with other proteins (32, 33, 34) . Future studies are necessary to identify the molecular target of somatostatin along this route.
In conclusion, our findings show for the first time that, by acting via a Pertussis toxin-sensitive receptor pathway, somatostatin can inhibit Rac activation. A very important consequence of this is that it can inhibit the motility and invasive behaviour of neuroblastoma cells (at least in vitro), thus suggesting that it might be taken into consideration as an in vivo anti-invasive agent that may abolish or at least reduce the metastatic process. by guest on 
